Abbott Raises 2026 EPS View to $5.45-$5.60 as Q2 Sales Climb 13%
Updated
Updated · PR Newswire · Jul 16
Abbott Raises 2026 EPS View to $5.45-$5.60 as Q2 Sales Climb 13%
3 articles · Updated · PR Newswire · Jul 16
Summary
Adjusted diluted EPS guidance rose to $5.45-$5.60 from $5.38-$5.58 after Abbott posted second-quarter adjusted EPS of $1.31 and GAAP EPS of $0.53.
Sales reached $12.59 billion, up 13.0% reported and 4.8% on a comparable basis, while Abbott kept its full-year comparable sales growth forecast at 6.5%-7.5%.
Medical devices led operating momentum with 8.4% comparable growth, while diagnostics grew 2.9% comparably; nutrition remained weak, down 3.6% on the same basis.
Abbott said second-half growth should accelerate, helped by recent milestones including Exact Sciences integration, CE Mark for Libre Duo and an FDA filing for the Amulet 360 device.
The company returned $2.1 billion to shareholders in the quarter and declared its 410th consecutive quarterly dividend of $0.63 a share.